EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:78277 - menaquinone-4
| Formula | C31H40O2 |
| Net Charge | 0 |
| Average Mass | 444.659 |
| Monoisotopic Mass | 444.30283 |
| SMILES | CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O |
| InChI | InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+ |
| InChIKey | DKHGMERMDICWDU-GHDNBGIDSA-N |
| Wikipedia |
|---|
| Species of Metabolite | Component | Source | Comments |
|---|---|---|---|
| Homo sapiens (ncbitaxon:9606) | blood plasma (BTO:0000118) | PubMed (32086127) |
| Roles Classification |
|---|
| Chemical Role: | antioxidant A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. |
| Biological Roles: | human metabolite Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). Escherichia coli metabolite Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. fat-soluble vitamin (role) Any vitamin that dissolves in fats and are stored in body tissues. Unlike the water-soluble vitamins, they are stored in the body for long periods of time and generally pose a greater risk for toxicity when consumed in excess. mouse metabolite Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. fat-soluble vitamin (role) Any vitamin that dissolves in fats and are stored in body tissues. Unlike the water-soluble vitamins, they are stored in the body for long periods of time and generally pose a greater risk for toxicity when consumed in excess. mouse metabolite Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| Applications: | neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. anti-inflammatory agent Any compound that has anti-inflammatory effects. antirheumatic drug A drug used to treat rheumatoid arthritis. anticoagulant An agent that prevents blood clotting. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antipsoriatic A drug used to treat psoriasis. dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. anti-arrhythmia drug A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. anti-inflammatory agent Any compound that has anti-inflammatory effects. antirheumatic drug A drug used to treat rheumatoid arthritis. anticoagulant An agent that prevents blood clotting. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antipsoriatic A drug used to treat psoriasis. dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. anti-arrhythmia drug A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. anti-inflammatory agent Any compound that has anti-inflammatory effects. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| menaquinone-4 (CHEBI:78277) has role anti-inflammatory agent (CHEBI:67079) |
| menaquinone-4 (CHEBI:78277) has role antineoplastic agent (CHEBI:35610) |
| menaquinone-4 (CHEBI:78277) has role antioxidant (CHEBI:22586) |
| menaquinone-4 (CHEBI:78277) has role bone density conservation agent (CHEBI:50646) |
| menaquinone-4 (CHEBI:78277) has role human metabolite (CHEBI:77746) |
| menaquinone-4 (CHEBI:78277) has role neuroprotective agent (CHEBI:63726) |
| menaquinone-4 (CHEBI:78277) is a menaquinone (CHEBI:16374) |
| Incoming Relation(s) |
| 2,3-epoxymenatetrenone (CHEBI:90152) has functional parent menaquinone-4 (CHEBI:78277) |
| ω-hydroxymenaquinone-4 (CHEBI:78278) has functional parent menaquinone-4 (CHEBI:78277) |
| IUPAC Name |
|---|
| 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1,4-naphthoquinone |
| INNs | Source |
|---|---|
| menatetrenona | WHO MedNet |
| menatetrenone | WHO MedNet |
| ménatétrénone | WHO MedNet |
| menatetrenonum | WHO MedNet |
| Synonyms | Source |
|---|---|
| 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthoquinone | ChemIDplus |
| 2-Methyl-3-geranylgeranyl-1,4-naphthoquinone | ChemIDplus |
| 2-Methyl-3-trans-tetraprenyl-1,4-naphthoquinone | ChemIDplus |
| Kaytwo | ChEMBL |
| Kaytwo n | ChEMBL |
| menaquinone 4 | ChEBI |
| UniProt Name | Source |
|---|---|
| menaquinone-4 | UniProt |
| Manual Xrefs | Databases |
|---|---|
| 1685 | DrugCentral |
| 4445530 | ChemSpider |
| CPD-9726 | MetaCyc |
| D00100 | KEGG DRUG |
| DB12148 | DrugBank |
| FDB029792 | FooDB |
| HMDB0030017 | HMDB |
| Menatetrenone | Wikipedia |
| Registry Numbers | Sources |
|---|---|
| Reaxys:2178866 | Reaxys |
| CAS:863-61-6 | ChemIDplus |
| Citations |
|---|